CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and ...

One-year results from the company's FORWARD-101 trial of islet cell therapy zimislecel (also known as VX-880) showed that all ...

US biopharma Vertex Pharmaceuticals and Japanese drugmaker Ono Pharmaceutical have announced an exclusive collaboration and ...

While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...

VX-880 stem cell therapy led to 92% reduction in insulin use, with 10 out of 12 patients eliminating injections entirely in a ...

"This edition of the Healthcare Enforcement column discusses two judicial decisions from recent months relating to the ...

With this reimbursement, approximately 45 people with cystic fibrosis in Australia will become eligible for a CFTR modulator for the first time –– ...

In phase 2 of the FORWARD study, 83% of participants with type 1 diabetes achieved insulin independence a year after receiving zimislecel (formerly VX-880), an islet cell therapy developed ...

Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B ...

As of 2021, 1.7 million adults in the United States were living with type 1 diabetes, according to statistics from the CDC.

OSAKA, Japan & BOSTON, MA, USA I June 23, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and ...

A dozen volunteers with severe type 1 diabetes showed clear improvements in their condition 12 months after receiving a ...